Transgene and BioInvent's BT-001 Shows Promising Antitumor Activity

Transgene and BioInvent have announced positive results for their oncolytic virus, BT-001, in combination with pembrolizumab. Presented at the 2025 European Society for Medical Oncology Annual Meeting, the data demonstrate the virus's significant antitumoral activity in advanced refractory tumors.

The combination therapy, which integrates Transgene's BT-001 with MSD's KEYTRUDA®, showcases encouraging tolerability and positive effects on both injected and non-injected lesions. Analyses reveal increased immune cell infiltration, with significant tumor shrinkage observed in multiple cases.

These findings underline BT-001's potential to convert "cold" tumors into active immune targets. Thus, further development in solid tumors is anticipated to enhance responses to cancer immunotherapies.